Inbal Avraham-Davidi,
Yona Ely,
Van N Pham,
Daniel Castranova,
Moshe Grunspan,
Guy Malkinson,
Liron Gibbs-Bar,
Oded Mayseless,
Gabriella Allmog,
Brigid Lo, [......],
Kenna Shaw,
Ilana Rogachev,
Wuzhou Wan,
Philip M Murphy,
Steven A Farber, Liran Carmel,
Gregory S Shelness,
M Luisa Iruela-Arispe,
Brant M Weinstein,
Karina Yaniv
[show abstract]
[hide abstract]
ABSTRACT: Despite the clear major contribution of hyperlipidemia to the prevalence of cardiovascular disease in the developed world, the direct effects of lipoproteins on endothelial cells have remained obscure and are under debate. Here we report a previously uncharacterized mechanism of vessel growth modulation by lipoprotein availability. Using a genetic screen for vascular defects in zebrafish, we initially identified a mutation, stalactite (stl), in the gene encoding microsomal triglyceride transfer protein (mtp), which is involved in the biosynthesis of apolipoprotein B (ApoB)-containing lipoproteins. By manipulating lipoprotein concentrations in zebrafish, we found that ApoB negatively regulates angiogenesis and that it is the ApoB protein particle, rather than lipid moieties within ApoB-containing lipoproteins, that is primarily responsible for this effect. Mechanistically, we identified downregulation of vascular endothelial growth factor receptor 1 (VEGFR1), which acts as a decoy receptor for VEGF, as a key mediator of the endothelial response to lipoproteins, and we observed VEGFR1 downregulation in hyperlipidemic mice. These findings may open new avenues for the treatment of lipoprotein-related vascular disorders.
Nature medicine 05/2012; 18(6):967-73. · 27.14 Impact Factor
